Microglia respond in a stereotypical pattern to a diverse array of pathological states. These changes are coupled to morphological and immunophenotypical alterations and the release of a variety of reactive species, trophic factors and cytokines that modify both microglia and their cellular environment. We examined whether a microglial-produced cytokine, tumour necrosis factor-α (TNF-α), was involved in the maintenance of microglial activation after spinal cord injury by selective inhibition using TNF-α antisense deoxyoligonucleotides (ASOs). Microglia and macrophages harvested from 3 d post-contused rat spinal cord were large and rounded (86.3 ± 9.6%). They were GSA-IB4-positive (GSA-IB4+) (Griffonia simplicifolia lectin, microglia specific; 94.8 ± 5.1%), strongly OX-42 positive (raised against a type 3 complement/integrin receptor, CD11b; 78.9 ± 9.1%), ED-1 positive (a lysosomal marker shown to correlate well with immune cell activation; 97.2 ± 2.6%) and IIA positive (antibody recognizes major histocompatibility complex II; 57.2 ± 5.6%), indicative of fully activated cells, for up to 48 h after plating. These cells also secreted significant amounts of TNF-α (up to 436 pg/μg total protein, 16 h). Fluoroscein isothiocyanate-labelled TNF-α ASOs (5, 50 and 200 nM) added to the culture medium were taken up very efficiently into the cells (> 90% cells) and significantly reduced TNF-α production by up to 92% (26.5 pg/μg total protein, 16 h, 200 nM TNF-α ASOs). Furthermore, few of the treated cells at this time were round (5.4 ± 2.7%), having become predominantly spindle shaped (74.9 ± 6.3%) or stellate (21.4 ± 2.7%); immunophenotypically, although all of them remained GSA-IB4 positive (91.6 ± 6.2%), many were weakly OX-42 positive and few expressed either ED-1 (12.9 ± 2.5%) or IIA (19.8 ± 7.4%). Thus, the secretion of TNF-α early in spinal cord injury may be involved in autoactivating microglia/macrophages. However, at the peak of microglial activation after injury, the activation state of microglia/macrophages is not stable and this process may still be reversible by blocking TNF-α.
- Gene therapy
ASJC Scopus subject areas